^
    Apply
    Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases (NCT00910728)
    Phase 1
    AstraZeneca
    Completed
    Last update posted :
    04/24/2017
    Initiation :
    05/01/2009
    Primary completion :
    03/01/2012
    Completion :
    08/01/2014
    JAK2
    |
    JAK2 mutation
    |
    AZD1480